From: Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy
 | Ischemic Events | Bleeding Events | ||||||
---|---|---|---|---|---|---|---|---|
Trial (observation period) | clop + ASA (%) | ASA + placebo (%) | p | NNT | clop + ASA (%) | ASA + placebo (%) | p | NNH |
Cure [36] (1 year) | 9.3 | 11.4 | <0.001 | 47.6 | major 3.7 minor 5.1 total 8.5 | major 2.7 minor 2.4 total 5.0 | <0.001 <0.001 <0.001 | 100 37 28.6 |
Credo [38] (1 years) | 8.5 | 11.2 | 0.02 | 37.0 | severe 8.8 minor 5.3 | severe 6.7 minor 5.6 | 0.07 0.92 | 250 |
Charisma [3] (2.5 years) | 6.8 | 7.3 | 0.22 | 200 | severe 1.7 moderate 2.1 moderate + severe 3.8 | severe1.3 moderate 1.3 moderate + severe 2.6 | 0.09 <0.001 <0.001 | 250 125 83.3 |